Effects Rapid Atrial Pacing Has on the Electrocardiogram (ECG) in Patients With Dual Chamber Pacemakers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00883610|
Recruitment Status : Completed
First Posted : April 17, 2009
Last Update Posted : December 11, 2014
|Condition or disease|
|Prolonged QT Interval|
This study requires a total of two study days as well as two follow up visits. During study day one, baseline blood will be drawn, a baseline electrocardiogram will be performed, and continuous QT Interval monitoring will be performed. The pacemaker rate will be increased to 90bpm at different time intervals and additional blood will be drawn to measure the effects of these rates changes.
On study day two, baseline blood will be drawn, a urine specimen will be obtained, an electrocardiogram will be performed, and continuous QT Interval monitoring will be performed. Following the acquisition of this information, the pacemaker rate will be decreased to 80bpm. We will obtain blood specimens, a urine specimen and an electrocardiogram at 30 minutes post rate change and again at 60 minutes post rate change.
Two days following the rate decrease to 80bpm, the patient will return to clinic to have their rate decreased to 70bpm. In two more days, the patient will return for a final rate change to 60bpm.
|Study Type :||Observational|
|Actual Enrollment :||12 participants|
|Official Title:||Modulation of QT Interval by Rapid Atrial Pacing in Patients With Dual Chamber Pacemakers|
|Study Start Date :||April 2009|
|Primary Completion Date :||June 2012|
|Study Completion Date :||June 2012|
- Determine the effect of abrupt changes in atrial rate on QT intervals [ Time Frame: 7 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00883610
|United States, Tennessee|
|Vanderbilt University Medical Center|
|Nashville, Tennessee, United States, 37232-8802|
|Principal Investigator:||Dawood Darbar, M.D., Ph.D., F.A.C.C.||Vanderbilt University Medical Center|